Meder
@itsmeder.bsky.social
December 15, 2020: Fabrizi et al., Pathogens (meta-analysis) found that acute kidney injury (AKI) is common in COVID-19, affecting about 1 in 6 hospitalized patients, rising to around half of severe cases, establishing kidney injury as a major COVID complication
December 21, 2025 at 5:33 AM
December 15, 2020: Fabrizi et al., Pathogens (meta-analysis) found that acute kidney injury (AKI) is common in COVID-19, affecting about 1 in 6 hospitalized patients, rising to around half of severe cases, establishing kidney injury as a major COVID complication
December 14, 2020: Harvey et al., Environmental Science & Technology Letters (longitudinal environmental surveillance) detected SARS-CoV-2 RNA on high-touch public surfaces but estimated the infection risk from touch as very low, reinforcing that fomites play a minimal role in transmission
December 21, 2025 at 5:33 AM
December 14, 2020: Harvey et al., Environmental Science & Technology Letters (longitudinal environmental surveillance) detected SARS-CoV-2 RNA on high-touch public surfaces but estimated the infection risk from touch as very low, reinforcing that fomites play a minimal role in transmission
December 9, 2020: Moreno-Arrones et al., JEDV (prospective multicenter clinical) found that COVID-19 can trigger telogen effluvium, a temporary but intense hair-shedding condition, typically starting about 2 months after infection, even in some mild or asymptomatic cases
December 21, 2025 at 5:33 AM
December 9, 2020: Moreno-Arrones et al., JEDV (prospective multicenter clinical) found that COVID-19 can trigger telogen effluvium, a temporary but intense hair-shedding condition, typically starting about 2 months after infection, even in some mild or asymptomatic cases
December 7, 2020: Wang et al., Science Translational Medicine (human immunology/antibody engineering study) showed that dimeric IgA, the antibody form found in the nose and throat, neutralizes SARS-CoV-2 far more effectively than standard antibodies
December 21, 2025 at 5:33 AM
December 7, 2020: Wang et al., Science Translational Medicine (human immunology/antibody engineering study) showed that dimeric IgA, the antibody form found in the nose and throat, neutralizes SARS-CoV-2 far more effectively than standard antibodies
December 7, 2020: Sterlin et al., Science Translational Medicine (longitudinal human immunology study) found that IgA dominates the early neutralizing antibody response to SARS-CoV-2, appearing before IgG, driving most early neutralization, and persisting longer at mucosal sites like saliva
December 21, 2025 at 5:33 AM
December 7, 2020: Sterlin et al., Science Translational Medicine (longitudinal human immunology study) found that IgA dominates the early neutralizing antibody response to SARS-CoV-2, appearing before IgG, driving most early neutralization, and persisting longer at mucosal sites like saliva
December 3, 2020: Pellegrini et al., Cell (human brain organoid and cell culture study) showed that SARS-CoV-2 can target the brain’s choroid plexus, damaging a key protective barrier and triggering inflammation
December 21, 2025 at 5:33 AM
December 3, 2020: Pellegrini et al., Cell (human brain organoid and cell culture study) showed that SARS-CoV-2 can target the brain’s choroid plexus, damaging a key protective barrier and triggering inflammation
December 3, 2020: Poston et al., Clinical Infectious Diseases (neutralization study) showed that antibodies from pre-pandemic seasonal coronavirus infections could neutralize common cold coronaviruses but did not neutralize SARS-CoV-2, arguing against widespread pre-existing antibody protection
December 21, 2025 at 5:33 AM
December 3, 2020: Poston et al., Clinical Infectious Diseases (neutralization study) showed that antibodies from pre-pandemic seasonal coronavirus infections could neutralize common cold coronaviruses but did not neutralize SARS-CoV-2, arguing against widespread pre-existing antibody protection
November 28, 2020: Vanaparthy et al., Cureus (case report) described a COVID patient who developed unusual post-infection effects including vestibular neuritis (severe vertigo), facial nerve spasms and Raynaud's, highlighting that COVID can trigger neurological and vascular symptoms beyond the lungs
December 21, 2025 at 5:33 AM
November 28, 2020: Vanaparthy et al., Cureus (case report) described a COVID patient who developed unusual post-infection effects including vestibular neuritis (severe vertigo), facial nerve spasms and Raynaud's, highlighting that COVID can trigger neurological and vascular symptoms beyond the lungs
November 25, 2020: Banerjee et al., Cell (lab study) showed that SARS-CoV-2 weakens the cell’s early immune defenses by blocking normal gene and protein production, helping the virus hide from interferons and spread more easily.
December 21, 2025 at 5:33 AM
November 25, 2020: Banerjee et al., Cell (lab study) showed that SARS-CoV-2 weakens the cell’s early immune defenses by blocking normal gene and protein production, helping the virus hide from interferons and spread more easily.
November 23, 2020: Kwon et al., Journal of Korean Medical Science (outbreak investigation) documented SARS-CoV-2 spread inside a restaurant where ceiling air conditioners directed airflow from an infected person to others up to 6.5 meters away after only minutes of exposure
December 21, 2025 at 5:33 AM
November 23, 2020: Kwon et al., Journal of Korean Medical Science (outbreak investigation) documented SARS-CoV-2 spread inside a restaurant where ceiling air conditioners directed airflow from an infected person to others up to 6.5 meters away after only minutes of exposure
November 15, 2020: Kanjwal et al., Journal of Innovations in Cardiac Rhythm Management (case report) documented new-onset postural orthostatic tachycardia syndrome (POTS) in an otherwise healthy female patient following COVID-19 infection
December 21, 2025 at 5:33 AM
November 15, 2020: Kanjwal et al., Journal of Innovations in Cardiac Rhythm Management (case report) documented new-onset postural orthostatic tachycardia syndrome (POTS) in an otherwise healthy female patient following COVID-19 infection
November 12, 2020: Clausen et al., Cell (lab/cell/virus assays) found SARS-CoV-2 does not just “grab” ACE2. It also latches onto heparan sulfate, a sugar coating on our cells, which helps the spike line up with ACE2
December 21, 2025 at 5:33 AM
November 12, 2020: Clausen et al., Cell (lab/cell/virus assays) found SARS-CoV-2 does not just “grab” ACE2. It also latches onto heparan sulfate, a sugar coating on our cells, which helps the spike line up with ACE2
November 4, 2020: Buchrieser et al., EMBO Journal (lab study) showed that SARS-CoV-2 can make infected cells fuse with nearby cells into large "giant cells" called syncytia, which may help explain some lung tissue damage in severe COVID
December 21, 2025 at 5:33 AM
November 4, 2020: Buchrieser et al., EMBO Journal (lab study) showed that SARS-CoV-2 can make infected cells fuse with nearby cells into large "giant cells" called syncytia, which may help explain some lung tissue damage in severe COVID
October 26, 2020: Seow et al., Nature (longitudinal immunology study) showed that neutralizing antibodies after SARS-CoV-2 infection decline within months, especially after mild illness, helping explain reinfections and why infection alone does not guarantee lasting immunity
December 21, 2025 at 5:33 AM
October 26, 2020: Seow et al., Nature (longitudinal immunology study) showed that neutralizing antibodies after SARS-CoV-2 infection decline within months, especially after mild illness, helping explain reinfections and why infection alone does not guarantee lasting immunity
October 15, 2020: Mathieu et al., JAAD Case Reports (case report) described new-onset pustular psoriasis appearing after COVID-19, in a patient with no prior psoriasis history.
December 21, 2025 at 5:33 AM
October 15, 2020: Mathieu et al., JAAD Case Reports (case report) described new-onset pustular psoriasis appearing after COVID-19, in a patient with no prior psoriasis history.
September 24, 2020: Bastard et al., Science (human immunology study) found that about 10 percent of patients with life-threatening COVID-19 had pre-existing autoantibodies that block type I interferons, crippling the body’s early antiviral defense.
December 21, 2025 at 5:33 AM
September 24, 2020: Bastard et al., Science (human immunology study) found that about 10 percent of patients with life-threatening COVID-19 had pre-existing autoantibodies that block type I interferons, crippling the body’s early antiviral defense.
September 24, 2020: Perego and Callard et al., Wellcome Open Research (open letter) explained why the patient-made term “Long Covid” is needed.
The term was first coined by Elisa Perego in May 2020 and helped give language and visibility to persistent, relapsing symptoms after SARS-CoV-2 infection
The term was first coined by Elisa Perego in May 2020 and helped give language and visibility to persistent, relapsing symptoms after SARS-CoV-2 infection
December 21, 2025 at 5:33 AM
September 24, 2020: Perego and Callard et al., Wellcome Open Research (open letter) explained why the patient-made term “Long Covid” is needed.
The term was first coined by Elisa Perego in May 2020 and helped give language and visibility to persistent, relapsing symptoms after SARS-CoV-2 infection
The term was first coined by Elisa Perego in May 2020 and helped give language and visibility to persistent, relapsing symptoms after SARS-CoV-2 infection
September 18, 2020: Choi et al., Emerging Infectious Diseases (epidemiologic investigation with viral genome sequencing) provided some of the strongest early evidence of in-flight transmission of SARS-CoV-2
December 21, 2025 at 5:33 AM
September 18, 2020: Choi et al., Emerging Infectious Diseases (epidemiologic investigation with viral genome sequencing) provided some of the strongest early evidence of in-flight transmission of SARS-CoV-2
September 14, 2020: Edridge et al., Nature (longitudinal cohort) analyzed 35 years of archived samples to show seasonal coronavirus reinfections and antibody waning, with evidence of reinfection as early as 6 months
December 21, 2025 at 5:33 AM
September 14, 2020: Edridge et al., Nature (longitudinal cohort) analyzed 35 years of archived samples to show seasonal coronavirus reinfections and antibody waning, with evidence of reinfection as early as 6 months
September 1, 2020: Kang et al., AIM (investigation) reported probable fecal aerosol transmission of SARS-CoV-2 in a high-rise building, showing virus spread between vertically aligned apartments through shared bathroom drainage pipes
December 21, 2025 at 5:33 AM
September 1, 2020: Kang et al., AIM (investigation) reported probable fecal aerosol transmission of SARS-CoV-2 in a high-rise building, showing virus spread between vertically aligned apartments through shared bathroom drainage pipes
August 25, 2020: To et al., Clinical Infectious Diseases (case report with whole-genome sequencing) confirmed the first documented COVID-19 reinfection.
A patient was infected twice by genetically distinct SARS-CoV-2 strains, proving reinfection was real and not just prolonged viral shedding
A patient was infected twice by genetically distinct SARS-CoV-2 strains, proving reinfection was real and not just prolonged viral shedding
December 21, 2025 at 5:33 AM
August 25, 2020: To et al., Clinical Infectious Diseases (case report with whole-genome sequencing) confirmed the first documented COVID-19 reinfection.
A patient was infected twice by genetically distinct SARS-CoV-2 strains, proving reinfection was real and not just prolonged viral shedding
A patient was infected twice by genetically distinct SARS-CoV-2 strains, proving reinfection was real and not just prolonged viral shedding
August 19, 2020: Kaneko et al., Cell (human tissue study) showed that severe COVID-19 can shut down germinal centers - the immune system’s antibody "training centers." Losing them helps explain why natural infection often produces weaker, short-lived antibodies and why reinfections happen
December 21, 2025 at 5:33 AM
August 19, 2020: Kaneko et al., Cell (human tissue study) showed that severe COVID-19 can shut down germinal centers - the immune system’s antibody "training centers." Losing them helps explain why natural infection often produces weaker, short-lived antibodies and why reinfections happen
August 11, 2020: Tcharkhtchi et al., Bioactive Materials (review) explains proper fit and multilayered technology (interception, diffusion, electrostatic charge) that attracts particles to make N95 masks effective
December 21, 2025 at 5:33 AM
August 11, 2020: Tcharkhtchi et al., Bioactive Materials (review) explains proper fit and multilayered technology (interception, diffusion, electrostatic charge) that attracts particles to make N95 masks effective
August 11, 2020: Mathew et al., Science (immunophenotyping cohort) showed that COVID-19 patients mount distinct immune response patterns, helping explain why outcomes vary so widely.
December 21, 2025 at 5:33 AM
August 11, 2020: Mathew et al., Science (immunophenotyping cohort) showed that COVID-19 patients mount distinct immune response patterns, helping explain why outcomes vary so widely.
August 6, 2020: Bouhaddou et al., Cell (cell biology) showed that COVID-19 can force infected cells to grow long finger-like extensions (filopodia) that carry virus particles, likely helping the virus spread directly from cell to cell in a way not commonly seen with other viruses.
December 21, 2025 at 5:33 AM
August 6, 2020: Bouhaddou et al., Cell (cell biology) showed that COVID-19 can force infected cells to grow long finger-like extensions (filopodia) that carry virus particles, likely helping the virus spread directly from cell to cell in a way not commonly seen with other viruses.